Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Keros Therapeutics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These actions are assigned to 3 distinct examiners and are located within 2 distinct art units, indicating a multi-faceted prosecution effort.
The busiest examiner for the company is PRIEST, JESSICA MARIE, who is handling 1 pending office action. With 3 pending office actions total and 3 distinct examiners, the workload is distributed evenly among the examiners. The presence of 2 distinct art units suggests that the company's biotechnology filings are categorized into at least 2 different specialized technical areas at the USPTO. This distribution requires the company to address the specific requirements of 2 different art units while coordinating with 3 different examiners across its 3 pending actions. The use of 3 distinct examiners for 3 pending actions shows that the company's current biotechnology prosecution is not concentrated under any single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| KAUFMAN, CLAIRE M | 1 | 63.5% | +50.7% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 60d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 60d |
| 17945324 | METHODS OF USING ACTIVIN RECEPTOR TYPE IIA VARIANTS | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443987 | METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORS | PRIEST, JESSICA MARIE | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 1674 | §102§103§112 | Non-Final OA | 60d | Pending | Apr 27, 2023 |
| 17945324 | METHODS OF USING ACTIVIN RECEPTOR TYPE IIA VARIANTS | BORGEEST, CHRISTINA M | 1675 | §103DP | Non-Final OA | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial